{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T23:15:16Z","timestamp":1778541316895,"version":"3.51.4"},"reference-count":25,"publisher":"Georg Thieme Verlag KG","issue":"05","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Geburtshilfe Frauenheilkd"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The ESGO-ESTRO-ESP guideline 2025 integrates the molecular classification into prognostic risk stratification and therapeutic decisions for patients with endometrial cancer (EC). In particular, a refined stratification of the molecular subgroup No-Specific-Molecular-Profile (NSMP) has been recently introduced to better reflect its pronounced prognostic heterogeneity. Retrospective analyses by Jamieson et al. and Vermij et al. demonstrate that histological tumor grade and immunohistochemical estrogen receptor expression represent independent prognostic factors within the NSMP subgroup, allowing for the identification of a large subgroup with an excellent prognosis and a small subgroup with a poor prognosis. Additional exploratory post hoc analyses suggest a potential differential benefit of adjuvant chemotherapy in ER-negative NSMP EC. However, these observations remain hypothesis-generating and lack prospective validation. In addition, the exact cut-off for ER-positivity remains unclear.The ESGO guideline defines prognostic risk groups according to the estimated 5-year risk of recurrence and derives recommendations for adjuvant therapy accordingly. Key randomized trials, including PORTEC-1, PORTEC-2, PORTEC-3, GOG-249 and GOG-258, are incorporated alongside molecular subgroups, whose biological characteristics increasingly inform treatment intensity. In contrast, the German S3 guideline adopts a more conservative methodological approach, incorporating molecular markers primarily as supportive information, particularly in the absence of prospective evidence guiding specific therapeutic decisions. With respect to surgical management in early-stage disease (F\u00e9d\u00e9ration Internationale de Gyn\u00e9cologie et d\u2019Obst\u00e9trique [FIGO] I\u2013II), both guidelines show substantial agreement, especially regarding the preference for minimally invasive surgery and the avoidance of unnecessary radicality. Differences mainly relate to the indication for sentinel lymph node staging. This statement aims to provide a balanced contextualization of these conceptual differences and to support an informed discussion of current international developments.<\/jats:p>","DOI":"10.1055\/a-2833-6208","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T22:36:46Z","timestamp":1778539006000},"page":"443-452","source":"Crossref","is-referenced-by-count":0,"title":["Statement by the Uterus Commission of the Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie [German Gynecological Oncology Group] (AGO) on the ESGO-ESTRO-ESP Guideline 2025"],"prefix":"10.1055","volume":"86","author":[{"given":"Beyhan","family":"Ataseven","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum OWL, Klinikum Lippe, Germany","place":["Detmold"],"department":["Universit\u00e4tsklinik f\u00fcr Frauenheilkunde und Geburtshilfe"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Battista","sequence":"additional","affiliation":[{"name":"Diakonie Klinikum Siegen, Germany","place":["Siegen"],"department":["Abt. Gyn\u00e4kologie und gyn\u00e4kologische Onkologie"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias W.","family":"Beckmann","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Erlangen, Germany","place":["Erlangen"],"department":["Frauenklinik"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Brucker","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsfrauenklinik T\u00fcbingen, Germany","place":["T\u00fcbingen"],"department":["Department f\u00fcr Frauengesundheit\/Forschungsinstitut f\u00fcr Frauengesundheit"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominik","family":"Denschlag","sequence":"additional","affiliation":[{"name":"Hochtaunus Kliniken, Germany","place":["Bad Homburg"],"department":["Frauenklinik"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Eichbaum","sequence":"additional","affiliation":[{"name":"Helios-Klinikum Wiesbaden, Germany","place":["Wiesbaden"],"department":["Frauenklinik"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanja","family":"Fehm","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum D\u00fcsseldorf, Germany","place":["D\u00fcsseldorf"],"department":["Klinik f\u00fcr Frauenheilkunde und Geburtshilfe"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Fleisch","sequence":"additional","affiliation":[{"name":"Helios Universit\u00e4tsklinikum Wuppertal, Germany","place":["Wuppertal"],"department":["Landesfrauenklinik"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerhard","family":"Gebauer","sequence":"additional","affiliation":[{"name":"Asklepios Klinik Barmbek, Germany","place":["Hamburg"],"department":["Frauenklinik"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Hillemanns","sequence":"additional","affiliation":[{"name":"Medizinische Hochschule Hannover, Germany","place":["Hannover"],"department":["Klinik f\u00fcr Frauenheilkunde und Geburtshilfe"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars Christian","family":"Horn","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Leipzig, Germany","place":["Leipzig"],"department":["Institut f\u00fcr Pathologie"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atanas","family":"Ignatov","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Magdeburg, Germany","place":["Magdeburg"],"department":["Universit\u00e4tsklinik f\u00fcr Frauenheilkunde, Geburtshilfe und Reproduktionsmedizin"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruediger","family":"Klapdor","sequence":"additional","affiliation":[{"name":"Albertinen Krankenhaus Hamburg, Germany","place":["Hamburg"],"department":["Klinik f\u00fcr Gyn\u00e4kologie und Geburtshilfe"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Marnitz-Schulz","sequence":"additional","affiliation":[{"name":"University Hospital Cologne, Germany","place":["K\u00f6ln"],"department":["Department of Radiation Oncology, CyberKnife and Radiotherapy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Radosa","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum des Saarlandes, Germany","place":["Homburg (Saar)"],"department":["Klinik f\u00fcr Gyn\u00e4kologie, Geburtshilfe und Reproduktionsmedizin"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Scholz","sequence":"additional","affiliation":[{"name":"M\u00fcnchen Klinik Harlaching, Germany","place":["M\u00fcnchen"],"department":["Frauenklinik"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Vordermark","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Halle (Saale), Germany","place":["Halle (Saale)"],"department":["Universit\u00e4tsklinik f\u00fcr Strahlentherapie"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clemens","family":"Tempfer","sequence":"additional","affiliation":[{"name":"Ruhr-Universit\u00e4t Bochum, Germany","place":["Herne"],"department":["Klinik f\u00fcr Gyn\u00e4kologie & Geburtshilfe"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"ref2","doi-asserted-by":"publisher","first-page":"e423","DOI":"10.1016\/S1470-2045(25)00167-6","article-title":"ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: update 2025","volume":"26","author":"N Concin","year":"2025","journal-title":"Lancet Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2022.100085","article-title":"Grade and Estrogen Receptor Expression Identify a Subset of No Specific Molecular Profile Endometrial Carcinomas at a Very Low Risk of Disease-Specific Death","volume":"36","author":"A Jamieson","year":"2023","journal-title":"Mod Pathol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1038\/s41416-023-02141-0","article-title":"Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry","volume":"128","author":"L Vermij","year":"2023","journal-title":"Br J Cancer"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ygyno.2025.05.015","article-title":"Prognostic significance of estrogen receptor expression and estrogen signaling in endometrial carcinomas of no specific molecular profile: A comprehensive molecular and pathologic analysis","volume":"198","author":"C Lam","year":"2025","journal-title":"Gynecol Oncol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/PGP.0000000000001112","article-title":"Clinicopathological and Molecular Characterization of High Grade Endometrial Carcinomas of No Specific Molecular Profile (NSMP) Stratified by ER Status","volume":"45","author":"PT Timmermans","year":"2026","journal-title":"Int J Gynecol Pathol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ygyno.2024.10.028","article-title":"Hormonal biomarkers remain prognostically relevant within the molecular subgroups in endometrial cancer","volume":"192","author":"SW Vrede","year":"2025","journal-title":"Gynecol Oncol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.3390\/cancers16183221","article-title":"Low-Risk and High-Risk NSMPs: A Prognostic Subclassification of No Specific Molecular Profile Subtype of Endometrial Carcinomas","volume":"16","author":"M Marchetti","year":"2024","journal-title":"Cancers (Basel)"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ygyno.2024.06.016","article-title":"The impact of estrogen receptor and L1 cell adhesion molecule expression on endometrial cancer outcome correlates with clinicopathological risk group and molecular subgroup","volume":"189","author":"K Aro","year":"2024","journal-title":"Gynecol Oncol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1200\/JCO.18.01575","article-title":"Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel\/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer","volume":"37","author":"ME Randall","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e573","DOI":"10.1016\/S1470-2045(25)00611-4","article-title":"It takes two to tango: importance of oestrogen receptor and progesterone receptor in endometrial cancer \u2013 Authors\u2019 reply","volume":"26","author":"T Bosse","year":"2025","journal-title":"Lancet Oncol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.3802\/jgo.2023.34.e85","article-title":"FIGO staging of endometrial cancer: 2023","volume":"34","author":"JS Berek","year":"2023","journal-title":"J Gynecol Oncol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S1470-2045(24)00142-6","article-title":"Prognostic impact and causality of age on oncological outcomes in women with endometrial cancer: a multimethod analysis of the randomised PORTEC-1, PORTEC-2, and PORTEC-3 trials","volume":"25","author":"FC Wakkerman","year":"2024","journal-title":"Lancet Oncol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/s41416-018-0310-8","article-title":"Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy","volume":"119","author":"BG Wortman","year":"2018","journal-title":"Br J Cancer"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S0140-6736(09)62163-2","article-title":"Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial","volume":"375","author":"RA Nout","year":"2010","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1097\/IGC.0b013e3182a5e77d","article-title":"Omitting adjuvant radiotherapy in endometrial cancer increases the rate of locoregional recurrences but has no effect on long-term survival: the Danish Endometrial Cancer Study","volume":"23","author":"G \u00d8rtoft","year":"2013","journal-title":"Int J Gynecol Cancer"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1097\/IGC.0b013e3182643ba0","article-title":"External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium-risk endometrial carcinoma: a prospective, randomized study--quality-of-life analysis","volume":"22","author":"BG Sorbe","year":"2012","journal-title":"Int J Gynecol Cancer"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1097\/IGC.0b013e3182a5e77d","article-title":"Omitting adjuvant radiotherapy in endometrial cancer increases the rate of locoregional recurrences but has no effect on long-term survival: the Danish Endometrial Cancer Study","volume":"23","author":"G \u00d8rtoft","year":"2013","journal-title":"Int J Gynecol Cancer"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/S1470-2045(19)30395-X","article-title":"Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial","volume":"20","author":"SM de Boer","year":"2019","journal-title":"Lancet Oncol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.1200\/JCO.20.00549","article-title":"Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy","volume":"38","author":"A Leon-Castillo","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1097\/OGX.0000000000001475","article-title":"Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3): 10-Year Clinical Outcomes and Post Hoc Analysis by Molecular Classification From a Randomized Phase 3 Trial","volume":"80","author":"CCB Post","year":"2025","journal-title":"Obstet Gynecol Surv"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1056\/NEJMoa1813181","article-title":"Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer","volume":"380","author":"D Matei","year":"2019","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer","volume":"388","author":"RN Eskander","year":"2023","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1056\/NEJMoa2302312","article-title":"Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer","volume":"388","author":"MR Mirza","year":"2023","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1056\/NEJMoa2409932","article-title":"ENGOT-en11\/GOG-3053\/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer","volume":"35","author":"T Van Gorp","year":"2024","journal-title":"Ann Oncol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1200\/JCO.23.02132","article-title":"Durvalumab Plus Carboplatin\/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial","volume":"42","author":"SN Westin","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Geburtshilfe und Frauenheilkunde"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2833-6208.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T22:36:51Z","timestamp":1778539011000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2833-6208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":25,"journal-issue":{"issue":"05","published-online":{"date-parts":[[2026,5,11]]},"published-print":{"date-parts":[[2026,5]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2833-6208","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0016-5751","1438-8804"],"issn-type":[{"value":"0016-5751","type":"print"},{"value":"1438-8804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]}}}